GLP-1 Awareness

In WHI 2026, 26.1% of the 6,968 urban working Indians who answered the question report any awareness of GLP-1 weight-loss medications — meaning they have at least heard the names Ozempic, Wegovy or Mounjaro. Eli Lilly's tirzepatide (Mounjaro) became India's top-selling drug by value within seven months of its March 2025 launch, generating ₹100 crore in monthly sales by October (Loop market note, GLP-1 Drug Landscape in India, 2026). The commercial story has moved faster than the public one: even after that launch, more than half of this urban, salaried, insured cohort — 54.4% — say they have never heard of these drugs at all.

This is a new question for WHI. There is no 2025 baseline. GLP-1 receptor agonists were not a meaningful presence in the Indian market a year before the survey window opened, so the page measures a standing start rather than a trend.

The structured-awareness band is narrow. Only 9.0% say they know what GLP-1s are and how they work; another 13.5% have heard the name but nothing more. The two are different states. The first is informed enough to discuss the drug with a physician; the second is exposed to the brand and little else. Most of what counts as "GLP-1 awareness" in India right now is the second kind.

Awareness rises 2.6× across the income scale, in step with the price tag#

Awareness climbs steadily with income above ₹6 lakh and more than doubles across the visible range. The shape is unusually clean for a survey cut — the same income gradient the Income & Job Role page traces through screening, supplementation and heavy-use behaviour. It is also the most economically legible finding on the page: a month of branded GLP-1 therapy costs ₹10,000–17,000 out of pocket, and no Indian health insurer currently covers the drug class for weight management (Loop market note, 2026). At a national median monthly income near ₹27,300, Wegovy alone consumes roughly 60% of typical earnings. The people most likely to have heard of the drug are, broadly, the people who could plausibly pay for it.

The lowest band (₹3–6 lakh, 20.9%) sits just below the under-₹3 lakh band (24.9%, not shown above for ordering clarity), which is the one wrinkle in an otherwise monotonic climb and likely reflects sample composition at the lowest end rather than a real reversal.

Among the diabetic and hypertensive, intent is four times higher — but a third have still never heard of the drug#

The cleanest way to read whether GLP-1s are reaching the people they were designed for is to split the survey by who already carries a metabolic diagnosis. The survey asks separately whether a doctor has diagnosed the respondent with diabetes or with hypertension. Grouping the two — anyone reporting either — gives an audience-level proxy for the population with established cardiometabolic disease.

Consider-or-use intent runs almost four times higher among people with a diagnosed metabolic condition — 10.6% against 2.7%. This is the finding that tells you the drug is being pulled toward clinical need, not only toward cosmetic demand. Indian guidelines position GLP-1s as second- or third-line therapy after metformin, favoured for patients with established cardiovascular disease, and 71.9% of Indian GLP-1 prescriptions are written for Type 2 diabetes rather than weight loss (Loop market note, 2026). The intent data is consistent with that prescribing reality.

The awareness side of the same table is where the gap is uncomfortable. Even among people who already have a diagnosis the drug can directly help, 37.3% have never heard of it — barely above the population baseline. A diagnosis brings a patient into contact with a physician, a pharmacy, and at least one annual blood panel. That contact is not, on this evidence, reliably surfacing a treatment option that is now the country's best-selling drug by value.

Women know more about GLP-1s; men are likelier to consider or use them#

Women are roughly ten points more aware of GLP-1s than men — 32.6% against 22.9%. Split by gender and age, the female lead holds at every band and widens with age, reaching 42.3% among women in their 50s. That fits the documented demographic of early Indian GLP-1 demand: the clinicians prescribing for weight loss describe their patient base as women from their 20s to early 50s (Loop market note, 2026).

The direction flips between the two metrics. Women lead on awareness; men lead on consideration-and-use at every age band where the sample supports a read. Knowing about the drug and intending to take it are not the same disposition here, and they sort by gender in opposite directions. The most plausible reading is a difference in how the drug is encountered: women appear to be the cohort tracking GLP-1s in the culture — through media, health content, social conversation, the same influencer and search channels the Health Information Sources page shows women leaning on more than men — while men, with a higher baseline burden of diagnosed metabolic disease in this dataset, arrive at intent through the clinic. Awareness flows down one channel, intent down another.

Awareness clusters in white-collar, high-income work — with healthcare and consulting at the top#

The industry ranking reads as an income-and-information map. Consulting tops it at 42.7%, consistent with the highest-income, most media-saturated white-collar cohort in the survey. Healthcare (36.4%) and Pharma (35.6%) sit close behind — but for a different reason. These are the two industries whose employees encounter GLP-1s professionally, not only as consumers, and the elevated awareness there is the least surprising number on the page. At the other end, Hospitality and Manufacturing — lower-income, less desk-bound, less plugged into the same media streams — sit below 22%. The variation tracks the income gradient more than anything industry-specific, with the healthcare and pharma exceptions proving the rule.

The addressable population dwarfs the aware one#

The spine of this page is the gap between two populations: the people who could benefit from a GLP-1 and the people who know one exists. WHI 2026 places 38.7% of urban working professionals in the glucose-dysfunction band on HbA1c testing — the metabolic-risk pool sitting in front of the diagnosed diabetic group (WHI 2026, Blood Sugar). That is the clinically addressable surface for a drug class whose primary indication is metabolic. Against it, 26.1% awareness — most of it the thin "heard the name" variety — and 3.6% consideration-or-use describe a market that has barely begun to map onto the need.

The market context says the gap is about to move. Semaglutide's secondary patent expires in March 2026, and 15-plus Indian manufacturers are preparing generic launches; industry projections put initial price cuts at 30–50%, with generic semaglutide potentially reaching ₹3,000–5,000 a month within a couple of years (Loop market note, 2026). At that price the affordability wall that currently shapes the income gradient on this page comes down. Awareness will follow availability. The question the WHI series will track is whether it follows it toward clinical need — the glucose-dysfunction band, the diagnosed diabetics, the lower-income workers who carry metabolic risk earliest — or whether it follows it back toward the cosmetic, higher-income demand where it started.